AVROBIO (AVRO)
(Delayed Data from NSDQ)
$1.39 USD
0.00 (0.00%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.40 +0.01 (0.72%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
AVROBIO, Inc. [AVRO]
Reports for Purchase
Showing records 61 - 80 ( 114 total )
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
2Q20; Gene Therapy Programs Humming Along, Additional Durability Shown
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Sustained Long-Term Benefit in Fabry, Cystinosis, Plus Early Plato Validation
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Tacit Admission on the Limitations of Busulfan Conditioning; Watching From Afar Till Alternative Matures in Late 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Financials; Big ASGCT Presence Up Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of April 27 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Ahead of the ASGCT 2020 Virtual Meeting - Read Through To Our Coverage
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of April 20 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of April 13 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Socially Distancing Ourselves From Lentiviruses; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts Post Clinical Updates; plato the Driver Going Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
LetÂ’s Caucus, or Never Again; In an Otherwise Ho-Hum Earnings Week
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Set to Unveil an Early Glimpse at plato; Precedence, Expectation, and Implications.
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D